AXSM vs. CORT, GBT, RARX, AIMT, HRMY, BMRN, BGNE, UTHR, VTRS, and SRPT
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Corcept Therapeutics (CORT), Global Blood Therapeutics (GBT), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Harmony Biosciences (HRMY), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), United Therapeutics (UTHR), Viatris (VTRS), and Sarepta Therapeutics (SRPT). These companies are all part of the "medical" sector.
Corcept Therapeutics (NASDAQ:CORT) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Corcept Therapeutics received 99 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.78% of users gave Corcept Therapeutics an outperform vote while only 68.86% of users gave Axsome Therapeutics an outperform vote.
Corcept Therapeutics currently has a consensus price target of $45.10, indicating a potential upside of 26.69%. Axsome Therapeutics has a consensus price target of $123.85, indicating a potential upside of 43.13%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Corcept Therapeutics.
Corcept Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics has a net margin of 22.38% compared to Corcept Therapeutics' net margin of -118.07%. Axsome Therapeutics' return on equity of 24.19% beat Corcept Therapeutics' return on equity.
93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Corcept Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
In the previous week, Axsome Therapeutics had 14 more articles in the media than Corcept Therapeutics. MarketBeat recorded 27 mentions for Axsome Therapeutics and 13 mentions for Corcept Therapeutics. Axsome Therapeutics' average media sentiment score of 1.02 beat Corcept Therapeutics' score of 0.65 indicating that Corcept Therapeutics is being referred to more favorably in the media.
Summary
Corcept Therapeutics beats Axsome Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
